Observed Signal · Sep 1, 2026 · corporate_event · Source: SEC API · Impact: 3.4/5
financials Market: 8-K Financial Filing Analysis for Humana (2026-09-01)
On September 1, 2026, Humana Inc. filed a Form 8-K announcing that senior management will reaffirm the company's full-year 2026 financial guidance during upcoming investor and analyst conferences throughout September. Humana continues to project full-year 2026 diluted GAAP EPS of at least $6.52 and non-GAAP Adjusted EPS of at least $9.00, maintaining the outlook originally issued on July 29, 2026. Furthermore, the company clarified that it will withhold commentary regarding the 2027 Medicare Advantage (MA) Star Ratings (Bonus Year 2028) until final data is officially published by the Centers for Medicare and Medicaid Services (CMS) in October.
Reaffirming annual EPS targets provides near-term earnings visibility and stability ahead of investor conferences, while deferring commentary on critical CMS Star Ratings keeps market attention focused on the upcoming October regulatory release.
Key Takeaways & Evidence Grounding
- Humana reaffirmed its full-year 2026 financial outlook, maintaining targets for diluted GAAP EPS of at least $6.52 and Adjusted EPS of at least $9.00.
- The guidance reconciliation reflects net adjustments of $2.48 per share, including put/call valuations ($1.47), value creation initiatives ($1.27), intangible amortization ($0.30), impairments ($0.17), and tax impacts ($(0.73)).
- Management explicitly deferred all commentary on 2027 Medicare Advantage Star Ratings (Bonus Year 2028) until CMS releases final ratings in October 2026.
Connected Companies & Entities
1 Entity mappedTrack Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.